CN101002973A - 具有聚合物涂层的导管 - Google Patents
具有聚合物涂层的导管 Download PDFInfo
- Publication number
- CN101002973A CN101002973A CNA2006100643374A CN200610064337A CN101002973A CN 101002973 A CN101002973 A CN 101002973A CN A2006100643374 A CNA2006100643374 A CN A2006100643374A CN 200610064337 A CN200610064337 A CN 200610064337A CN 101002973 A CN101002973 A CN 101002973A
- Authority
- CN
- China
- Prior art keywords
- conduit
- antimicrobial
- polymer
- inhibitory polymer
- chlorhexidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000011248 coating agent Substances 0.000 title description 14
- 238000000576 coating method Methods 0.000 title description 14
- 229920000642 polymer Polymers 0.000 claims abstract description 74
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 55
- 230000001028 anti-proliverative effect Effects 0.000 claims abstract description 14
- 229960000103 thrombolytic agent Drugs 0.000 claims abstract description 9
- 238000007920 subcutaneous administration Methods 0.000 claims abstract description 3
- 230000000845 anti-microbial effect Effects 0.000 claims description 48
- -1 poly(ethylene oxide) Polymers 0.000 claims description 26
- 239000002775 capsule Substances 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 16
- 208000007536 Thrombosis Diseases 0.000 claims description 16
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 12
- 229960003260 chlorhexidine Drugs 0.000 claims description 12
- 239000000975 dye Substances 0.000 claims description 12
- 102000009123 Fibrin Human genes 0.000 claims description 10
- 108010073385 Fibrin Proteins 0.000 claims description 10
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 10
- 229950003499 fibrin Drugs 0.000 claims description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 9
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 9
- 239000003527 fibrinolytic agent Substances 0.000 claims description 8
- 239000004812 Fluorinated ethylene propylene Substances 0.000 claims description 7
- 229920009441 perflouroethylene propylene Polymers 0.000 claims description 7
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 6
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 6
- 238000000502 dialysis Methods 0.000 claims description 6
- 229960003600 silver sulfadiazine Drugs 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 229960002152 chlorhexidine acetate Drugs 0.000 claims description 5
- 229960004023 minocycline Drugs 0.000 claims description 5
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims description 4
- 229940123208 Biguanide Drugs 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 4
- 230000002421 anti-septic effect Effects 0.000 claims description 4
- 239000003086 colorant Substances 0.000 claims description 4
- HCDGVLDPFQMKDK-UHFFFAOYSA-N hexafluoropropylene Chemical compound FC(F)=C(F)C(F)(F)F HCDGVLDPFQMKDK-UHFFFAOYSA-N 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 claims description 3
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 claims description 3
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 claims description 3
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 claims description 3
- 229930195573 Amycin Natural products 0.000 claims description 3
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 claims description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 3
- 235000000177 Indigofera tinctoria Nutrition 0.000 claims description 3
- 108060003100 Magainin Proteins 0.000 claims description 3
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 claims description 3
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 3
- 229920000153 Povidone-iodine Polymers 0.000 claims description 3
- 108010053950 Teicoplanin Proteins 0.000 claims description 3
- 239000004098 Tetracycline Substances 0.000 claims description 3
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 claims description 3
- 108010059993 Vancomycin Proteins 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 239000001000 anthraquinone dye Substances 0.000 claims description 3
- 150000004982 aromatic amines Chemical class 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 229960001506 brilliant green Drugs 0.000 claims description 3
- HXCILVUBKWANLN-UHFFFAOYSA-N brilliant green cation Chemical compound C1=CC(N(CC)CC)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](CC)CC)C=C1 HXCILVUBKWANLN-UHFFFAOYSA-N 0.000 claims description 3
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 claims description 3
- 229960001139 cefazolin Drugs 0.000 claims description 3
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 claims description 3
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 claims description 3
- 229960005443 chloroxylenol Drugs 0.000 claims description 3
- 229960002227 clindamycin Drugs 0.000 claims description 3
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 3
- 239000013078 crystal Substances 0.000 claims description 3
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 claims description 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 3
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 3
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 claims description 3
- JVICFMRAVNKDOE-UHFFFAOYSA-M ethyl violet Chemical compound [Cl-].C1=CC(N(CC)CC)=CC=C1C(C=1C=CC(=CC=1)N(CC)CC)=C1C=CC(=[N+](CC)CC)C=C1 JVICFMRAVNKDOE-UHFFFAOYSA-M 0.000 claims description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 3
- 229960002949 fluorouracil Drugs 0.000 claims description 3
- 230000026030 halogenation Effects 0.000 claims description 3
- 238000005658 halogenation reaction Methods 0.000 claims description 3
- 229960001915 hexamidine Drugs 0.000 claims description 3
- OQLKNTOKMBVBKV-UHFFFAOYSA-N hexamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 OQLKNTOKMBVBKV-UHFFFAOYSA-N 0.000 claims description 3
- 229940097275 indigo Drugs 0.000 claims description 3
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- NYGZLYXAPMMJTE-UHFFFAOYSA-M metanil yellow Chemical group [Na+].[O-]S(=O)(=O)C1=CC=CC(N=NC=2C=CC(NC=3C=CC=CC=3)=CC=2)=C1 NYGZLYXAPMMJTE-UHFFFAOYSA-M 0.000 claims description 3
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 claims description 3
- 229960000907 methylthioninium chloride Drugs 0.000 claims description 3
- 229960001774 octenidine Drugs 0.000 claims description 3
- SMGTYJPMKXNQFY-UHFFFAOYSA-N octenidine dihydrochloride Chemical compound Cl.Cl.C1=CC(=NCCCCCCCC)C=CN1CCCCCCCCCCN1C=CC(=NCCCCCCCC)C=C1 SMGTYJPMKXNQFY-UHFFFAOYSA-N 0.000 claims description 3
- 229960001621 povidone-iodine Drugs 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 3
- 229960005335 propanol Drugs 0.000 claims description 3
- 150000003222 pyridines Chemical class 0.000 claims description 3
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims description 3
- 229960001225 rifampicin Drugs 0.000 claims description 3
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 claims description 3
- 229930193551 sterin Natural products 0.000 claims description 3
- 229960001608 teicoplanin Drugs 0.000 claims description 3
- 229960002180 tetracycline Drugs 0.000 claims description 3
- 229930101283 tetracycline Natural products 0.000 claims description 3
- 235000019364 tetracycline Nutrition 0.000 claims description 3
- 150000003522 tetracyclines Chemical class 0.000 claims description 3
- 239000001003 triarylmethane dye Substances 0.000 claims description 3
- 229960003500 triclosan Drugs 0.000 claims description 3
- 229960003165 vancomycin Drugs 0.000 claims description 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 3
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims description 3
- 239000001018 xanthene dye Substances 0.000 claims description 3
- 238000002372 labelling Methods 0.000 claims description 2
- RHDGNLCLDBVESU-UHFFFAOYSA-N but-3-en-4-olide Chemical compound O=C1CC=CO1 RHDGNLCLDBVESU-UHFFFAOYSA-N 0.000 claims 4
- 230000032696 parturition Effects 0.000 claims 4
- 210000003462 vein Anatomy 0.000 claims 4
- 238000006243 chemical reaction Methods 0.000 claims 2
- 229950000845 politef Drugs 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 claims 1
- MOQOOKGPCBQMCY-UHFFFAOYSA-N acetic acid;hexane Chemical compound CC(O)=O.CCCCCC MOQOOKGPCBQMCY-UHFFFAOYSA-N 0.000 claims 1
- 230000002785 anti-thrombosis Effects 0.000 abstract description 8
- 239000004599 antimicrobial Substances 0.000 abstract description 7
- 229960004676 antithrombotic agent Drugs 0.000 abstract 1
- 230000003480 fibrinolytic effect Effects 0.000 abstract 1
- 230000002537 thrombolytic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 10
- 239000004814 polyurethane Substances 0.000 description 9
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 229920002635 polyurethane Polymers 0.000 description 8
- 239000003146 anticoagulant agent Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 5
- 230000010100 anticoagulation Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 229920001400 block copolymer Polymers 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- MUMXDRRTIYLYMY-YJKCNMNRSA-N (Z)-[dodecyl-[6-(dodecylazaniumyl)hexyl]amino]-oxido-oxidoiminoazanium Chemical compound CCCCCCCCCCCC[NH2+]CCCCCCN(CCCCCCCCCCCC)[N+](\[O-])=N\[O-] MUMXDRRTIYLYMY-YJKCNMNRSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001228 polyisocyanate Polymers 0.000 description 2
- 239000005056 polyisocyanate Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 230000007118 DNA alkylation Effects 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229920001730 Moisture cure polyurethane Polymers 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- KFNNRSFTPLQQPO-UHFFFAOYSA-N O1C(CC=C1)=O.O1C(CC=C1)=O Chemical class O1C(CC=C1)=O.O1C(CC=C1)=O KFNNRSFTPLQQPO-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000011195 Profilin Human genes 0.000 description 1
- 108050001408 Profilin Proteins 0.000 description 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
- 229940123361 Quorum sensing inhibitor Drugs 0.000 description 1
- 239000004433 Thermoplastic polyurethane Substances 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 125000002648 azanetriyl group Chemical group *N(*)* 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 150000002241 furanones Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229920001480 hydrophilic copolymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229920002803 thermoplastic polyurethane Polymers 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/0068—Static characteristics of the catheter tip, e.g. shape, atraumatic tip, curved tip or tip structure
- A61M25/007—Side holes, e.g. their profiles or arrangements; Provisions to keep side holes unblocked
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
- A61L2300/206—Biguanides, e.g. chlorohexidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0043—Catheters; Hollow probes characterised by structural features
- A61M2025/0056—Catheters; Hollow probes characterised by structural features provided with an antibacterial agent, e.g. by coating, residing in the polymer matrix or releasing an agent out of a reservoir
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials For Medical Uses (AREA)
Abstract
一种导管，包括具有第一端和第二端以及在所述第一端和第二端延伸的管腔的主体，位于邻近所述主体的第一端的第一部分和位于邻近所述主体的第二端的第二部分。抑制性聚合物设置在所述第一部分。所述抑制性聚合物包括一种或多种选自抗增殖剂、抗血栓生成剂、溶血栓剂和溶纤维蛋白剂的成分。抗微生物剂设置在所述第二部分。所述主体具有一定的长度以便当导管至少一部分被植入时所述第一端进入机体管道并且至少所述第二部分的一部分位于患者的皮下空间内。
Description
技术领域
【001】本发明涉及适于至少部分植入到体内的医疗设备。更具体地，本发明涉及具有治疗药物的导管。
背景
【002】诸如导管等的医疗设备在被植入时，与多种细胞、组织和身体***紧密接触放置，从而存在感染的可能。大体上，导管提供一条由外界环境进入到体内的通道，沿着该通道微生物可能寄居并最终导致感染。可能需要对感染的产生进行干涉，例如用治疗药物处理或甚至对医疗设备进行机械处理以去除微生物。更坏的情况是，需要移除和替换医疗设备以去除感染。总之，感染的存在会超过植入的优势。
【003】导管还可能引起其他涉及凝血的问题。具体地，公知的是当血液接触到除血管的天然壁之外的表面时，某些循环物质的激活将导致血液的凝固。如果在与血流接触的表面部分上形成血栓，将存在血栓被释放引起严重血液循环障碍，其被称之为血栓症的风险。
【004】因此，需要一种既能提供抗感染有效保护又能提供抗凝血特性的导管。
发明概述
【005】根据本发明的一个示例性实施方式，导管包括一个具有近端和远端的主体以及在所述主体的近端和远端之间延伸的管腔。在主体的近端设置有抗微生物剂。在主体的远端设置有抑制性聚合物。所述抑制性聚合物包括选自抗增殖剂、抗血栓生成剂、溶血栓剂和溶纤维蛋白剂中的一种或多种组分。
【006】根据本发明的另外一个示例性实施方式，导管包括具有第一端和第二端的主体，至少一个在所述第一端和第二端之间延伸的管腔，靠近所述主体的第一端的第一部分和靠近所述主体的第二端的第二部分。在所述第一部分设置有抑制性聚合物。所述抑制性聚合物包括选自抗增殖剂、抗血栓生成剂、溶血栓剂和溶纤维蛋白剂中的一种或多种组分。在所述第二部分设置有抗微生物剂。所述主体具有一定长度，以便当导管至少一部分被植入时所述第一端进入机体管道并且至少所述第二部分的一部分位于患者的皮下空间内。
【007】本发明的这些和其他的特性通过下文对本发明的多种示例性实施方式的详细描述进行说明或方便理解。
附图简述
【008】本发明的多种示例性实施方式将参照下面的附图进行详细的描述，其中：
【009】图1显示根据本发明的一种示例性实施方式的导管；
【0010】图2显示使用状态下的图1中的导管；
【0011】图3显示根据本发明的另外一种示例性实施方式的导管；
【0012】图4显示根据本发明的另外一种示例性实施方式的导管的一部分；
【0013】图5显示根据本发明的另外一种示例性实施方式的导管。
优选实施方式详述
【0014】本发明的多种示例性实施方式被图示为一种导管，其包括在导管的第一部分设置的抗微生物剂和在导管的第二部分设置的抑制性聚合物。此处所用的术语“设置”意指将一种物质通过任何适当的方式，诸如，例如，通过用所述物质涂覆所述表面或者通过将所述物质与导管材料混合安置在至少导管的表面上。
【0015】此处使用的术语“抑制性聚合物”意在涵盖具有诸如抗凝血或抗血栓特性的治疗性能的任何聚合物。本发明并不意味着限制为任何特定类型的导管，此处所述的导管结构主要用来示例。应当预见的是此处所述的治疗药物和聚合物涂层能应用于任何已知类型的导管设计。
【0016】图1显示根据本发明的一种示例性实施方式的导管10。导管10包括具有直径基本均匀的圆形横截面的主体12。主体12包括近端14和远端16。管腔18穿过主体12延伸并且终止于穿过主体12的远端16的端口20。主体12包括逐渐变细的末梢尖端22和多个纵向间隔开的端口或开口24，这些端口或开口24形成在主体12的靠近远端16的轴向间隔开的位置上。每一个开口24直接与管腔18相通。套筒26可以固定到主体12的近端上，用来和诸出袋或抽吸设备等适当的排出装置连接。导管10还可以包括分支线路28，用于，例如，在无需断开排出装置的情况下进行灌输或采样。分支线路28可以装配路厄配件30和夹子32，其用于在不使用时封闭分支线路28。
【0017】导管主体12可以由任何适合的生物相容性材料，诸如，例如，聚氨酯制得。并且，在一些实施方式中，主体12可以热固为曲线构形以利于***到体腔内。
【0018】在该实施方式中，将抗微生物剂36涂覆在靠近近端14的主体12的近端区域34上。此处所用的术语“抗微生物剂”意指对一种或多种微生物具有杀灭和抑制生长作用的任何药物。在本发明的示例性实施方式中，抗微生物剂36可浸透或药物扩散到近端区域34内。适合的抗微生物类药物包括抗生素、消毒剂和防腐剂。在优选实施方式中，抗微生物剂36包括一种或多种具有抵抗与留置套管的寄居和/或感染有关的普通微生物的活性。本发明可应用不同的抗微生物剂。其例子包括但不限于，胍(guanidium)(例如，双氯苯双胍己烷、双胍啶、己氧苯脒)，双胍，双吡啶例如奥替尼啶)，酚盐防腐剂(例如，colofoctol、氯二甲酚和三氯生)，以及烷基化氧，和芳族醚，硫醇，脂族胺，芳族胺和诸如F-、Br-、I-及其盐等的卤化物。另外的例子包括铋、gendine、genlenol、genlosan、genfoctol、磺胺嘧啶银、双氯苯双胍己烷-磺胺嘧啶银、双氯苯双胍己烷醋酸盐、双氯苯双胍己烷葡糖酸盐、双氯苯双胍己烷氢氯化物、双氯苯双胍己烷和丙醇、双氯苯双胍己烷基和双氯苯双胍己烷醋酸盐、聚维酮碘、头孢菌素V、替考拉宁、万古霉素、以及抗微生物染料和包含碳和铂的抗微生物混合物。所述抗微生物染料以是，例如，三芳基甲烷染料、单偶氮染料、重氮染料、靛蓝类染料、呫吨染料、荧光素染料、以及蒽醌染料或喹啉染料。关于染料的更多的特定例子包括龙胆紫、结晶紫、乙基紫、碱性亮绿、亚甲蓝。另外，不同的抗生素或抗生素的混合物可用于本发明。优选的抗生素的混合物通过不同的机制抑制细菌生长，例如，DNA或RNA复制抑制剂与蛋白合成抑制剂的混合物。通过抑制DNA或RNA复制从而抑制细菌的药物的例子包括利福平、taurolidone、5-氟尿嘧啶和阿霉素。抑制蛋白合成的药物的例子包括四环素，例如，二甲胺四环素和氯洁霉素。抗微生物剂的另外一个种类是定额敏感抑制剂(quorumsensing inhibitor)，例如自发诱导因子1(N-酰基高丝氨酸内酯)和自发诱导因子2(呋喃基硼酸二酯)的衍生物的抑制剂，它们的受体的抑制剂以及涉及它们的上调的基因和激酶的抑制剂。定额敏感抑制剂的例子包括呋喃酮(furanone)类，其中包括卤化呋喃酮类。还有另外一种抗微生物剂是宿主防御蛋白或缩氨酸，例如氨基固醇或马加宁，或者它们的类似物。另外的抗微生物剂的例子例如可由下述文献获得：美国专利号5221732，5643876，5840740，6303568，6388108和6875744，美国专利申请公开号2003/0078242，以及PCT国际公开号WO2004/099175，其内容被结合作为参考。优选地，抗微生物剂包含双氯苯双胍己烷(包括其游离碱及其盐和游离碱和盐的混合物)。
【0019】抗微生物剂36可以包括两种或多种抗微生物剂的组合。在这些实施方式中，所述两种或多种抗微生物剂能定位在近端区域34中的离散位置内或其上，或者所述两种或多种抗微生物剂可混合起来并均匀地分布在近端区域34之内或者其上。
【0020】抑制性聚合物38覆盖在主体12的邻近远端16的远端区域40上。抑制性聚合物优选是提供抗凝血、抗血栓、溶血栓、溶纤维蛋白或抗增殖特性的任何适合的聚合物，并且其优选抵抗蛋白沉积。抑制性聚合物38优选是亲水的。适合的抑制性聚合物的特定例子包括聚乙二醇(PEG)、聚环氧乙烷(PEO)、聚乙烯吡咯烷酮(PVP)、聚乙烯醇(PVA)以及磷酸胆碱(PC)。可选择地，抑制性聚合物还可以是疏水的，诸如，例如，氟化聚合物，包括聚四氟乙烯(PTFE)、六氟丙烯(HFP)、聚偏氟乙烯(PVDF)、或者氟化乙丙烯(FEP)。并且，抑制性聚合物可以包括释放生物活性药物的可降解的聚合物，诸如，例如，一氧化氮释放聚合物或聚阿司匹林。例如可参考，Parzuchowski，Pawel G.，Frost，MeganC和Meyerhoff，Mark E.“基于聚甲基丙烯酸酯的一氧化氮供体的合成和特征”，J.Am.Chen.Soc.2002，124，12182-12191。作为另外的例子，可以使用具有当其暴露在湿气中时可提供一氧化氮的配对二醇二氮烯功能团侧基的聚合物。例如可参考，Saavedra，Joseph E.和Keefer，Larry K，“氮基二醇二氮烯：用于生物医学研究和潜在临床应用的通用一氧化氮释放组合物”，J.Chem.educ.2002，79(12)，1427-1434。
【0021】掺入PEO和异氰酸盐的涂层是本领域公知的(Lambert的美国专利Nos.5459317，4487808和4585666；以及Fan等人的美国专利No.5558900)、另外，多元醇可以掺入到这种PEO/异氰酸盐涂层中以提供诱捕PEO的交联聚氨脂(PU)网(Elton的美国专利Nos.5077352和5179174)。PEO还可以与具有高分子量的结构塑料结合以提供具有降低了的摩擦的涂层(Rowland的美国专利No.5041100)。在本发明的优选实施方案中，抑制聚合物包括环氧乙烷，而抗微生物剂包括双氯苯双胍己烷。
【0022】PVP可单独或者与其他聚合物结合作为涂层使用。一种这样的涂层就是PVP-聚亚安酯共聚物(Micklus等的美国专利No.4100309和No.4119094)。另外一种类似的涂层包含PVP和线型预形成的聚氨酯的亲水混合物(Cresy的美国专利No.4642267)。另外，可以通过PVP溶液将聚异氰酸酯和多元醇结合从而将PVP结合到PU网中(Elton的美国专利Nos.5160790和5290585)。还有下一种类似的涂层可包含两层：底层和顶层。所述底层可以是包含自由异氰酸盐基团的聚氨酯预聚物，而顶层可以是PVP和诸如丙烯酰胺等具有活性氢基团的聚合物的亲水性共聚物(Winn的美国专利No.4373009)。
【0023】亲水性聚氨酯还可以用作抑制性聚合物38。例如，所述涂层可由包含聚异氰酸酯和分散在水成液相内的聚醚的随机混合物的聚氨酯水凝胶组成(Harada等的美国专利No.4118354)。聚氨酯还可以用作包含用各种亲水高分子量非氨基甲酸乙酯聚合物增链的亲水热塑性聚氨酯聚合物的组合物的涂层(Karkelle等人的美国专利No.4990357)。
【0024】特别地，PC已被证实能有效提供抗血栓涂层。这种涂层在Nakabayashi等人的美国专利No.5658561、Rowan的美国专利No.6673883、Bowers等人的美国专利No.5705583、Bowers等人的美国专利No.6090901和EP0593561中公开，这些文献的全文结合在此作为参考。
【0025】应当预见，抑制性聚合物可以运用任何适合的手段设置在导管的部分上，优选通过涂覆在导管的表面或通过将其与形成导管的材料混合。例如，可以使用在与导管材料混合后迁移到表面的嵌段共聚物，诸如，例如，聚氨酯-PEO或聚氨酯氟化嵌段共聚物，或者那些降解并向表面释放活性药物的嵌段共聚物。
【0026】适合的抑制性聚合物的其他例子可以包括螯合或结合来自循环血液的抗血栓因子的聚合物，例如像在美国专利申请公开2003/0185870A1中公开的那样，该文献的内容结合在此作为参考。并且，可以使用能够促进来自循环在血液中的潜伏效应子的治疗效用的聚合物，诸如，例如，包含由内生氮和亚硝基硫醇产生一氧化氮的配基的Cu(II)，如在美国专利申请公开说明书2002/0115559A1中公开的那样，其内容结合在此作为参考。也可以参考，B.Oh和M.E.Meyerhoff，“在掺杂亲脂性铜(II)复合物的聚合膜的界面上来自亚硝基硫醇的一氧化氮的自发产生”，J.Am.Chem.Soc. 2003，125，9552-3。
【0027】如图2所示，在使用时，导管10经由表皮42、真皮44和皮下层46穿过患者的皮肤到达脉管48。从而，涂覆在导管10的近端区域34上的治疗药物36能在导管10进入到表皮42和穿过皮下层46的位置提供抵抗感染的保护，而涂覆在导管10的远端区域40上的抑制性聚合物38能在皮下层46之下和脉管48内提供适当的抑制作用。
【0028】在一个可选的实施方式中，所述抗微生物剂36可以涂覆在导管10的整个主体12上，而不仅仅限于近端区域34上。从而，可以为整个导管10提供抵抗感染的保护。在另一个实施方式中，整个主体12涂覆有抑制性聚合物38。抗微生物药物36可以涂覆在抑制性聚合物38之上，或反之亦然。在本发明的另外的实施方式中，抗微生物剂36既可以涂覆在主体12的近端区域34上也可以涂覆在导管10的套筒26上。
【0029】图3显示了根据本发明的另外一个示例性实施方式的导管100。导管100是透析导管，包括具有近端104和远端106的主体102。第一和第二管腔108、110沿主体102延伸并在相应的端口112、114开口。导管主体102的近端104固定在连接套筒116上。第一连接管118和第二连接管120从连接套筒116延伸出来。连接套筒116将第一连接管118耦合在第一管腔108上以使其彼此连通，将第二连接管120耦合在第二管腔110上以使其彼此连通。连接翼122可以转动地固定在连接套筒116上以允许连接套筒116与患者的皮肤相固定。并且，一对夹子124和126可以分别地固定在连接管118和120上，以在每一次透析治疗之前和之后选择性地闭锁连接管118、120。一对路厄锁连接配件128和130分别地固定在连接管118和120的自由端，以允许导管100和补液线路、抽吸线路或透析机器的血液入口和血液返回端口相互连接。在后一种情况下，第一管腔108通过第一连接管118和路厄锁配件128耦合在透析机器的抽吸端口以从血管抽出含有毒素的血液；同时第二管腔110通过第二连接管120和路厄锁配件130耦合到透析机器的净化的血液返回端口以将净化的血液返回到血管。导管100还可以包含固定在接近近端104的导管的外部的稳定套囊140。
【0030】正如在前述实施方式中那样，抗微生物剂132涂覆在主体102的邻近近端104的近端区域134上，而抑制性聚合物136涂覆在邻近远端106的远端区域138上。在本发明的示例性实施方式中，抗微生物剂132可以浸透或药物扩散到近端区域134中。抗微生物剂132可以是一种或多种本文上文列出的抗微生物剂。抑制性聚合物优选是提供抗凝血、抗血栓、溶血栓、溶纤维蛋白或抗增殖特性的任何适合的聚合物，诸如本文在上文中列出的那些聚合物。并且，在另一个实施方式中，抗微生物剂132可以涂覆在导管100的整个主体102上，而不是仅仅涂覆在近端区域134上。可选地，整个主体102可以涂覆抑制性聚合物136。抗微生物剂132可以涂覆在抑制性聚合物136之上，或者反之亦然。还在另外的实施方式中，抗微生物剂132既可以涂覆在主体102的近端区域134上以及涂覆在连接套筒116和/或连接管118、120上。
【0031】在本发明的多种示例性实施方式中，导管涂覆抗微生物剂的区域可以在视觉上区别于涂覆有抑制性聚合物的区域。例如，如图4所示，隔离物142可以用来区别具有抗微生物剂132的区域和具有抑制性聚合物134的区域。在图4所示的实施方式中，隔离物142是可以印在主体102上的标记。可选地，每一个区域可以具有不同的颜色，或者区域可以由主体102上减小了直径的部分进行隔离。对导管上的不同区域进行识别能有助于装配和植入过程。
【0032】图5显示了根据本发明的另外一个示例性实施方式的导管200，其经由静脉切开位置260***到脉管270内。导管200具有与导管100大致相同的结构，包括路厄锁配件228、230，连接套筒216和套囊240。抗微生物剂212设置在导管200的近端区域，至少包括由套筒216到套囊240的区域。第一抑制性聚合物222，优选抗增殖的，设置在至少由套囊延伸到静脉切开位置260的中间区域220。第三抑制性聚合物250，优选是抗血栓的、溶血栓的或溶纤维蛋白的，设置在第一和第二管腔256和258的各自的远端区域252和254。从而，在该实施方式中，导管基本上包括三个区域：抗菌区域，抗增殖区域和抗血栓区域。在其他实施方式中，非聚合抗增殖剂可以设置在导管200的中间区域220，例如，诸如紫杉醇和DNA烷基化药物等的化学疗法制剂以及诸如雷帕霉素和雷帕霉素类似物等的mTOR抑制剂。
【0033】虽然已经对本发明的特定的实施方式进行了说明和描述，但在不脱离本发明的精神和范围的情况下能进行各种其他的变化和改进，这对于本领域技术人员来说是显而易见的。因此在附加的权利要求中想要涵盖落在本发明的范围内的所有变化和改进。
Claims (40)
1、一种导管，包括：
主体，具有近端部分、远端部分以及在所述主体的近端部分和远端部分之间延伸的管腔；
设置在所述主体的近端部分的抗微生物剂；以及
设置在所述主体的远端部分的抑制性聚合物，所述抑制性聚合物包含一种或多种选自抗增殖剂、抗血栓生成剂、溶血栓剂和溶纤维蛋白剂的组分。
2、如权利要求1所述的导管，其中所述整个主体设置有所述抑制性聚合物。
3、如权利要求2所述的导管，其中所述抑制性聚合物设置在所述抗微生物剂之上。
4、如权利要求2所述的导管，其中所述抗微生物剂设置在所述抑制性聚合物之上。
5、如权利要求1所述的导管，其中所述整个主体设置有抗微生物剂。
6、如权利要求5所述的导管，其中所述抑制性聚合物设置在所述抗微生物剂之上。
7、如权利要求5所述的导管，其中所述抗微生物剂设置在所述抑制性聚合物之上。
8、如权利要求1所述的导管，其中所述抑制性聚合物包括聚乙二醇、聚环氧乙烷、聚乙烯吡咯烷酮、聚乙烯醇、聚四氟乙烯、六氟丙烯、聚偏氟乙烯、氟化乙丙烯、一氧化氮释放聚合物、促进内生抑制性底物转化的聚合物或螯合内生抗血栓生成剂的聚合物。
9、如权利要求1所述的导管，其中所述抑制性聚合物包含聚环氧乙烷。
10、如权利要求1所述的导管，其中所述抗微生物剂包括下列药物中的一种或多种：胍，双胍，双吡啶，酚盐防腐剂，烷基化氧，芳族醚，硫醇，脂族胺，芳族胺，colofoctol，氯二甲酚，三氯生，gendine，genlenol，genlosan，genfoctol，奥替尼啶，双氯苯双胍己烷，双胍啶，己氧苯脒，磺胺嘧啶银，双氯苯双胍己烷-磺胺嘧啶银，双氨苯双胍己烷醋酸盐，双氯苯双胍己烷葡糖酸盐，双氯苯双胍己烷氢氯化物，双氯苯双胍己烷和丙醇，双氯苯双胍己烷碱和双氯苯双胍己烷醋酸盐，聚维酮碘，头孢菌素V，替考拉宁，万古霉素，氨基固醇，马加宁，呋喃酮，卤化呋喃酮，三芳基甲烷染料，单偶氮染料，重氮染料，靛蓝类染料，呫吨染料，荧光素染料，蒽醌染料，喹啉染料，龙胆紫，结晶紫，乙基紫，碱性亮绿，亚甲蓝，利福平，taurolidone，5-氟尿嘧啶，阿霉素，四环素，二甲胺四环素，氯洁霉素，利福平-二甲胺四环素，以及它们的盐。
11、如权利要求1所述的导管，其中所述抗微生物剂包括双氯苯双胍己烷。
12、如权利要求11所述的导管，其中所述抑制性聚合物包括聚环氧乙烷。
13、如权利要求1所述的导管，其中所述近端部分包括套筒。
14、如权利要求1所述的导管，其中所述近端部分包括至少一个连接管。
15、如权利要求1所述的导管，其中所述近端部分包括套囊。
16、如权利要求1所述的导管，其中所述近端部分包括套筒和套囊，并且所述抗微生物剂至少在所述套筒至所述套囊之间扩展。
17、如权利要求1所述的导管，其中所述近端部分包括套囊，所述抑制性聚合物包含抗增殖剂并至少在所述套囊至静脉切口之间扩展。
18、如权利要求1所述的导管，其中所述远端部分终止于末梢尖端，所述抑制性聚合物包含抗血栓生成剂、溶血栓剂或溶纤维蛋白剂并设置在所述末梢尖端。
19、如权利要求1所述的导管，其中所述近端部分包括套筒和套囊，所述抗微生物剂至少在所述套筒到所述套囊之间扩展，所述抑制性聚合物包括至少在所述套囊到静脉切口之间扩展的抗增殖剂和设置在所述远端部分的末梢尖端的抗血栓生成剂、溶血栓剂或溶纤维蛋白剂。
20、一种导管，包括：
具有第一端和第二端的主体，至少一个在所述第一端和第二端之间延伸的管腔，靠近所述主体的第一端的第一部分和靠近所述主体的第二端的第二部分，设置在所述第一部分的抑制性聚合物，所述抑制性聚合物包括选自抗增殖剂、抗血栓生成剂、溶血栓剂和溶纤维蛋白剂的一种或多种组分，以及设置在所述第二端的抗微生物剂，
所述主体具有一定长度，以便当导管至少一部分被植入时所述第一端进入机体管道并且至少所述第二部分的一部分位于患者的皮下空间内。
21、如权利要求20所述的导管，其中所述整个主体上设置有所述抑制性聚合物。
22、如权利要求21所述的导管，其中所述抑制性聚合物设置在所述抗微生物剂之上。
23、如权利要求21所述的导管，其中所述抗微生物剂设置在所述抑制性聚合物之上。
24、如权利要求20所述的导管，其中所述整个主体设置有抗微生物剂。
25、如权利要求24所述的导管，其中所述抑制性聚合物设置在所述抗微生物剂之上。
26、如权利要求24所述的导管，其中所述抗微生物剂设置在所述抑制性聚合物之上。
27、如权利要求20所述的导管，其中所述抑制性聚合物包括聚乙二醇、聚环氧乙烷、聚乙烯吡咯烷酮、聚乙烯醇、聚四氟乙烯、六氟丙烯、聚偏氟乙烯、氟化乙丙烯、一氧化氮释放聚合物、促进内生抑制性底物转化的聚合物或螯合内生抗血栓生成剂的聚合物。
28、如权利要求20所述的导管，其中所述抗微生物剂包括下列药物中的一种或多种：胍，双胍，双吡啶，酚盐防腐剂，烷基化氧，芳族醚，硫醇，脂族胺，芳族胺，colofoctol，氯二甲酚，三氯生，gendine，genlenol，genlosan，genfoctol，奥替尼啶，双氯苯双胍己烷，双胍啶，己氧苯脒，磺胺嘧啶银，双氯苯双胍己烷-磺胺嘧啶银，双氯苯双胍己烷醋酸盐，双氯苯双胍己烷葡糖酸盐，双氯苯双胍己烷氢氯化物，双氯苯双胍己烷和丙醇，双氯苯双胍己烷碱和双氯苯双胍己烷醋酸盐，聚维酮碘，头孢菌素V，替考拉宁，万古霉素，氨基固醇，马加宁，呋喃酮，卤化呋喃酮，三芳基甲烷染料，单偶氮染料，重氮染料，靛蓝类染料，呫吨染料，荧光素染料，蒽醌染料，喹啉染料，龙胆紫，结晶紫，乙基紫，碱性亮绿，亚甲蓝，利福平，taurolidone，5-氟尿嘧啶，阿霉素，四环素，二甲胺四环素，氯洁霉素，利福平-二甲胺四环素，以及它们的盐。
29、如权利要求20所述的导管，其中所述抗微生物剂包括双氯苯双胍己烷。
30、如权利要求29所述的导管，其中所述抑制性聚合物包括聚环氧乙烷。
31、如权利要求20所述的导管，其中所述导管是透析导管。
32、如权利要求31所述的导管，其中所述至少一个管腔包括引入管腔和出口管腔。
33、如权利要求20所述的导管，其中所述主体还包括用于隔开所述第一部分和第二部分的间隔物。
34、如权利要求33所述的导管，其中所述间隔物是一个标记。
35、如权利要求20所述的导管，其中所述第二部分包括套筒。
36、如权利要求20所述的导管，其中所述第二部分包括套囊。
37、如权利要求20所述的导管，其中所述第二部分包括套筒和套囊，所述抗微生物剂至少在所述套筒到所述套囊之间扩展。
38、如权利要求20所述的导管，其中所述第二部分包括套囊，并且所述抑制性聚合物包括抗增殖剂并至少在所述套囊到静脉切口之间扩展。
39、如权利要求20所述的导管，其中所述第一部分终止于导管尖端，所述抑制性聚合物包括抗血栓生成剂、溶血栓剂或溶纤维蛋白剂并设置在所述导管尖端上。
40、如权利要求20所述的导管，其中所述第二部分包括套筒和套囊，所述抗微生物剂至少在所述套筒到所述套囊之间扩展，并且所述抑制性聚合物包括至少在套囊至静脉切口之间扩展的抗增殖剂和设置在所述导管尖端的抗血栓生成剂、溶血栓剂或溶纤维蛋白剂。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/293,056 | 2005-12-02 | ||
| US11/293,056 US20070129690A1 (en) | 2005-12-02 | 2005-12-02 | Catheter with polymeric coating |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101002973A true CN101002973A (zh) | 2007-07-25 |
Family
ID=38092803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006100643374A Pending CN101002973A (zh) | 2005-12-02 | 2006-12-04 | 具有聚合物涂层的导管 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20070129690A1 (zh) |
| EP (1) | EP1960031A4 (zh) |
| CN (1) | CN101002973A (zh) |
| WO (1) | WO2007064835A2 (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102481391A (zh) * | 2009-07-09 | 2012-05-30 | 贝克顿·迪金森公司 | 用于皮肤侵入性装置的抗微生物涂层 |
| CN102500033A (zh) * | 2011-11-04 | 2012-06-20 | 北京迪玛克医药科技有限公司 | 抗感染静脉导管及其制备方法 |
| CN102149408B (zh) * | 2008-09-15 | 2013-11-13 | Cv智巧有限公司 | 水溶性和不溶于水的治疗剂向体腔表面的局部递送 |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8414547B2 (en) * | 2004-04-29 | 2013-04-09 | C. R. Bard, Inc. | Modulating agents for antimicrobial coatings |
| CA2912259C (en) | 2005-05-27 | 2020-04-28 | Mark H. Schoenfisch | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
| GB2438873A (en) * | 2006-06-08 | 2007-12-12 | Univ Hull | Determining correct positioning of a catheter |
| US10188826B2 (en) * | 2006-09-29 | 2019-01-29 | Covidien Lp | Catheters including antimicrobial sleeve and methods of making catheters |
| US20080188830A1 (en) * | 2007-02-06 | 2008-08-07 | Arrow International, Inc. | Selectively reinforced medical devices |
| EP2209472A1 (en) * | 2007-10-12 | 2010-07-28 | The University of North Carolina at Chapel Hill | Use of nitric oxide to enhance the efficacy of silver and other topical wound care agents |
| US8496629B2 (en) | 2008-04-22 | 2013-07-30 | Becton, Dickinson And Company | Catheter hole having a flow breaking feature |
| US9399112B2 (en) | 2008-04-22 | 2016-07-26 | Becton, Dickinson And Company | Catheter hole having an inclined trailing edge |
| US7959598B2 (en) | 2008-08-20 | 2011-06-14 | Asante Solutions, Inc. | Infusion pump systems and methods |
| US20100082097A1 (en) * | 2008-10-01 | 2010-04-01 | Joel Rosenblatt | Article Containing Segregated Biguanide and Lewis Acid |
| KR101099518B1 (ko) | 2009-02-09 | 2011-12-27 | 연세대학교 산학협력단 | 카테터 및 이의 제조방법 |
| US8545459B2 (en) * | 2009-02-25 | 2013-10-01 | Teleflex Medical Incorporated | Stabilized enzyme compositions |
| US9333280B2 (en) * | 2009-02-25 | 2016-05-10 | Teleflex Medical Incorporated | Stabilized enzyme compositions |
| US11219706B2 (en) | 2009-03-11 | 2022-01-11 | Arrow International Llc | Enhanced formulations for coating medical devices |
| US20100233288A1 (en) * | 2009-03-11 | 2010-09-16 | Teleflex Medical Incorporated | Medical devices containing nitroprusside and antimicrobial agents |
| CN102695528B (zh) | 2009-08-21 | 2016-07-13 | 诺万公司 | 创伤敷料、其使用方法及其形成方法 |
| US9526738B2 (en) | 2009-08-21 | 2016-12-27 | Novan, Inc. | Topical gels and methods of using the same |
| US8992959B2 (en) | 2010-12-10 | 2015-03-31 | Medline Industries, Inc. | Articles having antimicrobial properties and methods of manufacturing the same |
| ES2695173T3 (es) | 2011-02-28 | 2019-01-02 | Novan Inc | Partículas de sílice modificadas con S-nitrosotiol que liberan óxido nítrico y procedimientos de fabricación de las mismas |
| WO2012131044A1 (en) * | 2011-03-30 | 2012-10-04 | Unomedical A/S | Subcutaneous inserter device |
| EP2722069B1 (en) | 2011-06-15 | 2018-01-03 | Terumo Kabushiki Kaisha | Sheath for introducer and introducer assembly |
| US9320873B2 (en) * | 2011-06-15 | 2016-04-26 | Terumo Kabushiki Kaisha | Introducer sheath and introducer assembly |
| WO2013149186A1 (en) | 2012-03-30 | 2013-10-03 | Insulet Corporation | Fluid delivery device with transcutaneous access tool, insertion mechansim and blood glucose monitoring for use therewith |
| US20140005605A1 (en) * | 2012-06-28 | 2014-01-02 | Pacesetter, Inc. | Use of quorum sensing inhibitors and biofilm dispersing agents for controlling biofilm-associated implantable medical device related infections |
| US9750928B2 (en) | 2013-02-13 | 2017-09-05 | Becton, Dickinson And Company | Blood control IV catheter with stationary septum activator |
| US9695323B2 (en) | 2013-02-13 | 2017-07-04 | Becton, Dickinson And Company | UV curable solventless antimicrobial compositions |
| US9327095B2 (en) | 2013-03-11 | 2016-05-03 | Becton, Dickinson And Company | Blood control catheter with antimicrobial needle lube |
| US9750927B2 (en) | 2013-03-11 | 2017-09-05 | Becton, Dickinson And Company | Blood control catheter with antimicrobial needle lube |
| JP6594295B2 (ja) | 2013-04-18 | 2019-10-23 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 抗菌カテーテル |
| US9535043B2 (en) * | 2013-05-31 | 2017-01-03 | Empire Technology Development Llc | Color change indicator of biofilm formation |
| US20150141965A1 (en) * | 2013-11-15 | 2015-05-21 | Celeste V. Bonham | Tubing for mitigating against microbial migration and method and system for maintaining closed-system of urinary tubing |
| GB2523989B (en) | 2014-01-30 | 2020-07-29 | Insulet Netherlands B V | Therapeutic product delivery system and method of pairing |
| US9789279B2 (en) | 2014-04-23 | 2017-10-17 | Becton, Dickinson And Company | Antimicrobial obturator for use with vascular access devices |
| US10376686B2 (en) | 2014-04-23 | 2019-08-13 | Becton, Dickinson And Company | Antimicrobial caps for medical connectors |
| US9675793B2 (en) | 2014-04-23 | 2017-06-13 | Becton, Dickinson And Company | Catheter tubing with extraluminal antimicrobial coating |
| US10610677B2 (en) | 2014-05-19 | 2020-04-07 | Celeste V. Bonham | Urological system that includes connector with integrated non-return check valve for extension tubing and urology collection systems |
| US20150359957A1 (en) * | 2014-06-13 | 2015-12-17 | Cook Medical Technologies Llc | Axially split foam peritoneal dialysis catheter design with functional coatings |
| US10232088B2 (en) | 2014-07-08 | 2019-03-19 | Becton, Dickinson And Company | Antimicrobial coating forming kink resistant feature on a vascular access device |
| WO2016118569A1 (en) | 2015-01-22 | 2016-07-28 | Hollister Incorporated | Lubricious urinary catheters having varying flexibility |
| RU2580281C1 (ru) * | 2015-02-05 | 2016-04-10 | Открытое акционерное общество "ГосНИИсинтезбелок" (ОАО "ГосНИИсинтезбелок") | Защитное покрытие катетеров |
| WO2016134137A1 (en) | 2015-02-18 | 2016-08-25 | Insulet Corporation | Fluid delivery and infusion devices, and methods of use thereof |
| ES2926678T3 (es) | 2015-03-30 | 2022-10-27 | Bard Inc C R | Aplicación de agentes antimicrobianos a dispositivos médicos |
| US10493244B2 (en) | 2015-10-28 | 2019-12-03 | Becton, Dickinson And Company | Extension tubing strain relief |
| US10413665B2 (en) | 2015-11-25 | 2019-09-17 | Insulet Corporation | Wearable medication delivery device |
| WO2017112878A1 (en) | 2015-12-22 | 2017-06-29 | Access Vascular, Inc. | High strength biomedical materials |
| WO2017123525A1 (en) | 2016-01-13 | 2017-07-20 | Bigfoot Biomedical, Inc. | User interface for diabetes management system |
| CN113101448B (zh) | 2016-01-14 | 2024-01-23 | 比格福特生物医药公司 | 调整胰岛素输送速率的*** |
| US10363342B2 (en) * | 2016-02-04 | 2019-07-30 | Insulet Corporation | Anti-inflammatory cannula |
| WO2018058041A1 (en) | 2016-09-23 | 2018-03-29 | Insulet Corporation | Fluid delivery device with sensor |
| US10610668B2 (en) | 2016-10-05 | 2020-04-07 | Becton, Dickinson And Company | Catheter with an asymmetric tip |
| WO2018132765A1 (en) | 2017-01-13 | 2018-07-19 | Mazlish Bryan | Insulin delivery methods, systems and devices |
| US11052234B2 (en) | 2017-02-15 | 2021-07-06 | Celeste V. Bonham | Connector with integrated non-return check valve for extension tubing and urology collection systems |
| WO2018156548A1 (en) | 2017-02-22 | 2018-08-30 | Insulet Corporation | Needle insertion mechanisms for drug containers |
| CN110997026A (zh) | 2017-06-21 | 2020-04-10 | 阿塞斯血管有限公司 | 并入有水溶性聚合物的高强度多孔材料 |
| WO2019067367A1 (en) | 2017-09-26 | 2019-04-04 | Insulet Corporation | NEEDLE MECHANISM MODULE FOR DRUG DELIVERY DEVICE |
| US11147931B2 (en) | 2017-11-17 | 2021-10-19 | Insulet Corporation | Drug delivery device with air and backflow elimination |
| USD928199S1 (en) | 2018-04-02 | 2021-08-17 | Bigfoot Biomedical, Inc. | Medication delivery device with icons |
| US11565043B2 (en) | 2018-05-04 | 2023-01-31 | Insulet Corporation | Safety constraints for a control algorithm based drug delivery system |
| WO2020069406A1 (en) | 2018-09-28 | 2020-04-02 | Insulet Corporation | Activity mode for artificial pancreas system |
| WO2020077223A1 (en) | 2018-10-11 | 2020-04-16 | Insulet Corporation | Event detection for drug delivery system |
| USD920343S1 (en) | 2019-01-09 | 2021-05-25 | Bigfoot Biomedical, Inc. | Display screen or portion thereof with graphical user interface associated with insulin delivery |
| US11801344B2 (en) | 2019-09-13 | 2023-10-31 | Insulet Corporation | Blood glucose rate of change modulation of meal and correction insulin bolus quantity |
| US11935637B2 (en) | 2019-09-27 | 2024-03-19 | Insulet Corporation | Onboarding and total daily insulin adaptivity |
| EP4069082B1 (en) | 2019-12-06 | 2024-06-05 | Insulet Corporation | Techniques and devices providing adaptivity and personalization in diabetes treatment |
| US11833329B2 (en) | 2019-12-20 | 2023-12-05 | Insulet Corporation | Techniques for improved automatic drug delivery performance using delivery tendencies from past delivery history and use patterns |
| US11551802B2 (en) | 2020-02-11 | 2023-01-10 | Insulet Corporation | Early meal detection and calorie intake detection |
| US11986630B2 (en) | 2020-02-12 | 2024-05-21 | Insulet Corporation | Dual hormone delivery system for reducing impending hypoglycemia and/or hyperglycemia risk |
| US11547800B2 (en) | 2020-02-12 | 2023-01-10 | Insulet Corporation | User parameter dependent cost function for personalized reduction of hypoglycemia and/or hyperglycemia in a closed loop artificial pancreas system |
| US11324889B2 (en) | 2020-02-14 | 2022-05-10 | Insulet Corporation | Compensation for missing readings from a glucose monitor in an automated insulin delivery system |
| US11607493B2 (en) | 2020-04-06 | 2023-03-21 | Insulet Corporation | Initial total daily insulin setting for user onboarding |
| EP4171704A1 (en) | 2020-06-30 | 2023-05-03 | Access Vascular, Inc. | Articles comprising markings and related methods |
| US11684716B2 (en) | 2020-07-31 | 2023-06-27 | Insulet Corporation | Techniques to reduce risk of occlusions in drug delivery systems |
| US11904140B2 (en) | 2021-03-10 | 2024-02-20 | Insulet Corporation | Adaptable asymmetric medicament cost component in a control system for medicament delivery |
| US11738144B2 (en) | 2021-09-27 | 2023-08-29 | Insulet Corporation | Techniques enabling adaptation of parameters in aid systems by user input |
| US11439754B1 (en) | 2021-12-01 | 2022-09-13 | Insulet Corporation | Optimizing embedded formulations for drug delivery |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4118354A (en) | 1972-11-24 | 1978-10-03 | Dai-Ichi Kogyo Seiyaku Co., Ltd. | Polyurethane hydrogel and method for the production of the same |
| US4119094A (en) | 1977-08-08 | 1978-10-10 | Biosearch Medical Products Inc. | Coated substrate having a low coefficient of friction hydrophilic coating and a method of making the same |
| US4100309A (en) | 1977-08-08 | 1978-07-11 | Biosearch Medical Products, Inc. | Coated substrate having a low coefficient of friction hydrophilic coating and a method of making the same |
| US4373009A (en) | 1981-05-18 | 1983-02-08 | International Silicone Corporation | Method of forming a hydrophilic coating on a substrate |
| SE430695B (sv) | 1982-04-22 | 1983-12-05 | Astra Meditec Ab | Forfarande for framstellning av en hydrofil beleggning samt enligt forfarandet framstellda medicinska artiklar |
| US4487808A (en) | 1982-04-22 | 1984-12-11 | Astra Meditec Aktiebolag | Medical article having a hydrophilic coating |
| US4569673A (en) * | 1984-01-12 | 1986-02-11 | Battelle Development Corporation | Bacterial barrier for indwelling catheters and other medical devices |
| US4642267A (en) | 1985-05-06 | 1987-02-10 | Hydromer, Inc. | Hydrophilic polymer blend |
| US5643876A (en) | 1987-03-04 | 1997-07-01 | The United States Of America As Represented By The Department Of Health And Human Services | Biologically active synthetic magainin peptides |
| CA1327311C (en) | 1987-07-06 | 1994-03-01 | Jesse M. Jaynes | Therapeutic antimicrobial polypeptides, their use and methods for preparation |
| US5221732A (en) | 1988-12-06 | 1993-06-22 | The United States Of America As Represented By The Department Of Health And Human Services | Antimicrobial magainin modified peptides |
| US5041100A (en) | 1989-04-28 | 1991-08-20 | Cordis Corporation | Catheter and hydrophilic, friction-reducing coating thereon |
| US4990357A (en) | 1989-05-04 | 1991-02-05 | Becton, Dickinson And Company | Elastomeric segmented hydrophilic polyetherurethane based lubricious coatings |
| US5077352A (en) | 1990-04-23 | 1991-12-31 | C. R. Bard, Inc. | Flexible lubricious organic coatings |
| US5179174A (en) | 1990-04-23 | 1993-01-12 | C. R. Bard, Inc. | Flexible lubricious organic coatings |
| US5160790A (en) | 1990-11-01 | 1992-11-03 | C. R. Bard, Inc. | Lubricious hydrogel coatings |
| US6090901A (en) | 1991-07-05 | 2000-07-18 | Biocompatibles Limited | Polymeric surface coatings |
| US5705583A (en) | 1991-07-05 | 1998-01-06 | Biocompatibles Limited | Polymeric surface coatings |
| CA2277953C (en) | 1991-07-05 | 2001-01-16 | Biocompatibles Limited | Polymeric surface coatings |
| JPH05220218A (ja) | 1992-02-13 | 1993-08-31 | Norio Nakabayashi | 抗血栓性再生セルロース系膜及びその製造方法 |
| US5324275A (en) * | 1992-10-02 | 1994-06-28 | Board Of Regeants, University Of Texas System | Antimicrobial medical devices |
| US5688516A (en) * | 1992-11-12 | 1997-11-18 | Board Of Regents, The University Of Texas System | Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices |
| US5459317A (en) | 1994-02-14 | 1995-10-17 | Ohio University | Method and apparatus for non-invasive detection of physiological chemicals, particularly glucose |
| US5840740A (en) | 1995-06-07 | 1998-11-24 | Magainin Pharmaceuticals Inc. | Aminosterol compounds and a method of treating infection using the aminosterol compounds |
| US5558900A (en) | 1994-09-22 | 1996-09-24 | Fan; You-Ling | One-step thromboresistant, lubricious coating |
| US5820607A (en) * | 1995-06-05 | 1998-10-13 | Board Of Regents, University Of Texas Systems | Multipurpose anti-microbial silastic sheath system for the prevention of device-related infections |
| US6673883B1 (en) | 1997-01-10 | 2004-01-06 | Biocompatibles Uk Limited | Polymers containing zwitterionic monomers |
| AU773038B2 (en) | 1998-08-12 | 2004-05-13 | Genaera Corporation | Aminosterol compounds and uses thereof |
| AU771367B2 (en) * | 1998-08-20 | 2004-03-18 | Cook Medical Technologies Llc | Coated implantable medical device |
| US6168580B1 (en) * | 1999-03-26 | 2001-01-02 | Iontophoretics Corporation | Antimicrobial device and methods for long-term catheters |
| US6716895B1 (en) * | 1999-12-15 | 2004-04-06 | C.R. Bard, Inc. | Polymer compositions containing colloids of silver salts |
| WO2002082907A1 (en) | 2001-01-12 | 2002-10-24 | Board Of Regents, The University Of Texas System | Novel antiseptic derivatives with broad spectrum antimicrobial activity for the impregnation of surfaces |
| US6837848B2 (en) * | 2003-01-15 | 2005-01-04 | Medtronic, Inc. | Methods and apparatus for accessing and stabilizing an area of the heart |
| US7128904B2 (en) | 2001-01-16 | 2006-10-31 | The Regents Of The University Of Michigan | Material containing metal ion ligand complex producing nitric oxide in contact with blood |
| US6875744B2 (en) | 2001-03-28 | 2005-04-05 | Helix Biomedix, Inc. | Short bioactive peptides |
| US6921390B2 (en) * | 2001-07-23 | 2005-07-26 | Boston Scientific Scimed, Inc. | Long-term indwelling medical devices containing slow-releasing antimicrobial agents and having a surfactant surface |
| ATE434184T1 (de) * | 2001-11-20 | 2009-07-15 | Univ Duke | Grenzflächen-biomaterialien |
| JP2005511144A (ja) * | 2001-12-03 | 2005-04-28 | シー・アール・バード・インク | 微生物耐性医療用具、微生物耐性ポリマーコーティング及びその製造方法 |
| EP1475092A1 (en) | 2003-05-06 | 2004-11-10 | 4Sc Ag | Blockers of the quorum sensing system of Gram-negative bacteria |
| US20030208166A1 (en) * | 2002-05-06 | 2003-11-06 | Schwartz Anthony H. | Implantable device with free-flowing exit and uses thereof |
| EP2324866B1 (en) * | 2002-07-12 | 2014-06-18 | Cook Medical Technologies LLC | Angioplasty balloons drug-coated in an expanded condition |
| ES2346214T3 (es) * | 2003-02-26 | 2010-10-13 | Coloplast A/S | Dispositivo medico con un recubrimiento que comprende peroxido de hidrogeno y envase para el mismo. |
| US7306580B2 (en) * | 2003-04-16 | 2007-12-11 | Cook Incorporated | Medical device with therapeutic agents |
-
2005
- 2005-12-02 US US11/293,056 patent/US20070129690A1/en not_active Abandoned
-
2006
- 2006-12-01 WO PCT/US2006/045918 patent/WO2007064835A2/en active Application Filing
- 2006-12-01 EP EP06838731A patent/EP1960031A4/en not_active Withdrawn
- 2006-12-04 CN CNA2006100643374A patent/CN101002973A/zh active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102149408B (zh) * | 2008-09-15 | 2013-11-13 | Cv智巧有限公司 | 水溶性和不溶于水的治疗剂向体腔表面的局部递送 |
| CN102481391A (zh) * | 2009-07-09 | 2012-05-30 | 贝克顿·迪金森公司 | 用于皮肤侵入性装置的抗微生物涂层 |
| CN102481391B (zh) * | 2009-07-09 | 2015-04-08 | 贝克顿·迪金森公司 | 用于皮肤侵入性装置的抗微生物涂层 |
| CN102500033A (zh) * | 2011-11-04 | 2012-06-20 | 北京迪玛克医药科技有限公司 | 抗感染静脉导管及其制备方法 |
| CN102500033B (zh) * | 2011-11-04 | 2014-08-13 | 北京迪玛克医药科技有限公司 | 抗感染静脉导管及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007064835A3 (en) | 2007-10-18 |
| WO2007064835A2 (en) | 2007-06-07 |
| EP1960031A4 (en) | 2011-06-01 |
| EP1960031A2 (en) | 2008-08-27 |
| US20070129690A1 (en) | 2007-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101002973A (zh) | 具有聚合物涂层的导管 | |
| US20080188830A1 (en) | Selectively reinforced medical devices | |
| US4623329A (en) | Drainage and infusion catheters having a capillary sleeve forming a reservoir for a fluid antimicrobial agent | |
| ES2282529T3 (es) | Composicion para la prevencion de una infeccion debida a un dispositi vo permanente. | |
| AU730158B2 (en) | Triclosan-containing medical devices | |
| AU2017397418B2 (en) | Catheter system for continuous irrigation | |
| ES2232022T3 (es) | Material plastico esponjoso desinfectante. | |
| US7195615B2 (en) | System for providing a medical device with anti-microbial properties | |
| US8906401B2 (en) | Antimicrobial medical devices containing chlorhexidine free base and salt | |
| CA2522408C (en) | Medical device with therapeutic agents | |
| US20060095020A1 (en) | Introduction of agent with medical device | |
| CN108136153A (zh) | 改进的导尿管、成套工具及方法 | |
| IE58945B1 (en) | Method for preparing infection-resistant materials | |
| KR20080052624A (ko) | 항균성 카테터 | |
| ES2306716T3 (es) | Disolucion de sellado de cateteres que incluye un foto-oxidante. | |
| JPH08141088A (ja) | 弁付きカニューレ | |
| CN212547923U (zh) | 一种非涂层抗菌导尿管 | |
| KR20180101767A (ko) | 카테터용 조성물, 그를 이용하여 제조된 중심 정맥 카테터 및 혈관 내 튜브 카테터 | |
| CN112826810B (zh) | 一种预防经皮置管导管外表面感染的联合杨梅素/唑类药物的涂膜剂及其应用 | |
| US20240198040A1 (en) | Liquid medication-injecting urinary catheter | |
| AU767489B2 (en) | Triclosan-containing medical devices | |
| JPH0420347A (ja) | 医療用具 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |